Abstract
Atrial fibrillation (AF) represents the most frequent sustained cardiac arrhythmia, the prevalence of AF is 1-2 % in the general population and up to 6 % for population over 80 years. Arterial hypertension (AH) is the commonest background comorbidity in patients with AF. Patients with AF have 3-6‑fold increased risk of ischemic stroke in comparison to that in general population, additionally the presence of AH leads an 2-3‑fold increase in risk of subsequent stroke. Current clinical guidelines recommend long-time anticoagulant treatment for prevention of stroke and thromboembolic complications in majority of patients with confirmed AF. Not only does uncontrolled high blood pressure contribute to developing new-onset AF or AF progression but also can increase a bleeding risk related to oral anticoagulants. Patients with AF and concomitant AH resulting in target organ damage need for more favorable safety profile of oral anticoagulants. Instruction label dabigatran treatment in two doses can individualize approach to choice of long-term anticoagulation with lower risk of major bleeding in AF patients.
Highlights
additionally the presence of Arterial hypertension (AH) leads an 2–3‐fold increase in risk of subsequent stroke
uncontrolled high blood pressure contribute to developing new-onset Atrial fibrillation (AF)
a bleeding risk related to oral anticoagulants
Summary
Atrial fibrillation (AF) represents the most frequent sustained cardiac arrhythmia, the prevalence of AF is 1–2 % in the general population and up to 6 % for population over 80 years. Instruction label dabigatran treatment in two doses can individualize approach to choice of long-term anticoagulation with lower risk of major bleeding in AF patients. Фибрилляция предсердий (ФП) является самым частым нарушением ритма сердца, ее распространенность в общей популяции составляет 1–2 %, а среди лиц старше 80 лет – 15 % [1,2,3]. Фибрилляция предсердий вдвое увеличивает риск смерти независимо от наличия других ее предикторов и представляется основной причиной кардиоэмболических мозговых инсультов и длительной нетрудоспособности пациентов [6, 7]. Подтвержденный диагноз ФП требует, согласно текущим рекомендациям, помимо контроля ритма сердца или ЧСС, проведения постоянной антикоагулянтной терапии (АКТ) у большинства пациентов с целью профилактики тромбоэмболических осложнений (ТЭО) [12]. В данном обзоре мы попытались представить обновленную информацию об эпидемиологии ФП и АГ и более детально остановиться на практических аспектах АКТ у пациентов с АГ и ФП, принимая во внимание накопленный опыт применения дабигатрана
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
